Chimerix Inc., a biopharmaceutical firm dedicated to developing life-extending medication, has made significant progress with its pipeline products. Among its many initiatives is the Phase 2 clinical trial of ONC201, a program aimed at treating glioma patients with tumors that have the H3 K27M mutation. ONC206, another imipridone product, acts as a dopamine receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist, with a higher level of non-competitive DRD2 antagonism than ONC201. It is currently in Phase I clinical trials for solid tumor treatment. Additionally, ONC212 is an imipridone agonist aimed at the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for pancreatic cancer, solid tumors, and hematological malignancies like leukemias. CMX521, a nucleoside analog antiviral drug candidate, is another noteworthy project of the company, with a focus on treating SARS-CoV-2 (COVID-19) infections. SymBio Pharmaceuticals has agreed to partner with Chimerix Inc. to develop and commercialize TEMBEXA for other human diseases, including smallpox, as per the licensing agreement. Chimerix Inc., founded in 2000, operates out of Durham, North Carolina.
Chimerix's ticker is CMRX
The company's shares trade on the NASDAQ stock exchange
They are based in Durham, North Carolina
There are 51-200 employees working at Chimerix
Chimerix is in the Healthcare sector
Chimerix is in the Biotechnology industry
The following five companies are Chimerix's industry peers: